Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine

A technology of antigenic peptides and drugs, applied in the field of malignant tumor bioimmune drugs, can solve problems such as difficult side effects and non-specificity

Inactive Publication Date: 2018-07-06
天津亨佳生物科技发展有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, DCs induced by tumor-associated high-expression proteins are not strictly specific, and tissue cells other than tumors also express the same protein, so its side effects are a problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine
  • Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine
  • Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Patient A, female, 49 years old. Right lung adenocarcinoma, multiple lymph node metastasis, clinical stage IV, lung tumor with iodine 125 seed implantation once, progressed after 3 times of gemcitabine single-agent chemotherapy, liver metastases progressed after chemoembolization, EGFR molecular targeted drug resistance . Multiple lung metastases, liver metastases, pleural metastases, bone metastases, and abdominal lymph node metastases. Biopsy of lung lesions was taken, whole exome sequencing and HLA typing microarray were performed. The patient carried EGFR p.T790M, and the HLA typing was HLA-A: A*0216 A*3002; HLA-B: B*1502 B*5801; HLA-C: C*0303 C*1203; HLA-DQB1: DQB1*0401 DQB1*0602; HLA-DRB1: DRB1*1101 DRB1*1501.

[0066] Use the specific tumor antigen peptide chain combination therapy of the present invention once a week for a total of 6 weeks. The secretion of specific CD8+ Tetramer+ T cells was detected by spot detection before and after the injection of the an...

Embodiment 2

[0071]Patient B, male, 73 years old, lung squamous cell carcinoma, liver metastases, no indication for surgery, 6 weeks of pemetrexed + cisplatin intravenous chemotherapy, progression after 1 cycle of pemetrexed chemotherapy, iodine 125 seed implantation Progress after admission. After whole exome sequencing and HLA typing chip detection, the results showed that the patient carried EGFR p.T790M mutation, and the HLA typing was HLA-A: A*0202 A*0212; HLA-B: B*0702 B*0808; HLA-C: C*0401 C*0701; HLA-DQB1: DQB1*030302 DQB1*0601; HLA-DRB1: DRB1*0401 DRB1*1002.

[0072] Combination therapy was performed using the tumor-treating antigen peptide chain group of the present invention, once a week for a total of 12 weeks. The specific selected peptide chains are as follows: SEQ ID No: 3+SEQ ID No: 4+SEQ ID No: 7+SEQ ID No: 23+SEQ ID No: 28+SEQ ID No: 30.

[0073] Changes in lung tumor size before and after treatment image 3 shown, by image 3 It can be seen that the size of the left ...

Embodiment 3-60

[0075] Example 3-60 Different types and degrees of cancer patients were selected and treated with different combinations of antigen peptide groups, once a week for a total of 12 weeks. The HLA*A3101-HVKITDFGR Tetramer staining results of Example 3-60 and the changes in the size of lung tumors before and after treatment were similar to those in Example 1-2. Due to space limitations, they will not be repeated here. The above results all indicate that the antigen peptide chain group of the present invention can induce tumor-producing dendritic cells, and dendritic cells, which are antigen-presenting cells, can present antigen information to T cells, interact with T cells, and make T cells produce It specifically kills tumor cells and plays a role in killing tumor cells, and the effect is obvious.

[0076] During the treatment of Example 1-60, ELISA was used to detect the secretion of specific IFN-γ before the use of the antigen peptide chain, 3 weeks, 7 weeks and 11 weeks after a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antigen peptide chain group for tumor individualized biological immunotherapy and application of the antigen peptide chain group in medicine. The antigen peptide chain groupfor treating tumor comprises any one amino acid sequence or a combination of at least two amino acid sequences in SEQ ID No:1 to SEQ ID No:30. The antigen peptide chain group disclosed by the invention is capable of inducing dendritic cells generating the tumor, so that antigen information can be presented to T cells by the dendritic cells used as antigen presenting cells, the antigen peptide chain group can interact with the T cells, specific anti-tumor cells can be generated by the T cells, and a function of killing tumor cells can be achieved.

Description

technical field [0001] The invention belongs to the technical field of biological immune medicine for malignant tumors, and particularly relates to an antigen peptide chain group for individualized biological immune therapy of tumors and its application in medicine. Background technique [0002] At present, the global incidence of malignant tumors is increasing day by day, with high mortality and poor prognosis. The National Cancer Center's National Cancer Prevention and Research Office released China's largest cancer survival data summary analysis data in the International Journal of Cancer. The data shows that the 5-year cancer survival rate in China is 30.9%, which is far lower than the level of developed countries; at the same time, the survival rate of rural patients is only half of urban patients. In developed countries, prostate cancer and breast cancer account for the majority. In China, lung cancer, gastric cancer, liver cancer and other cancers are more common. Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K7/08A61K39/00A61P35/00
CPCC07K7/06A61K39/0011C07K7/08
Inventor 刘玉强孙旭东李晓丹
Owner 天津亨佳生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com